TY  - JOUR
SN  - 1687-6121
UR  - https://doi.org/10.1155/2019/3480732
ID  - discovery10071996
N2  - OBJECTIVES:
Our aim of this study is to compare the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis patients in the Chinese population. 

// METHODS:  
Both the RevMan 5.2 and the Stata 12.0 software are used in this study for analysis, and a fixed-effect model (the Mantel-Haenszel method) or a random-effect model (the DerSimonian and Laird method) is used to merge or aggregate the risk ratio (RR) and its 95% confidence intervals (CI) of included studies. 

// RESULTS:
Eleven trials involving 654 ulcerative colitis patients (treated group: 328; control group: 326) were analyzed in this study. Significant differences (RR = 1.29, 95% CI = 1.20 to 1.40, P < 0.001) between patients were observed between the two groups. 

// CONCLUSIONS:
Our results suggested that the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis is better than traditional drug treatments.
A1  - Zhou, X
A1  - Zhao, L
A1  - Yang, P
A1  - Chen, Y
A1  - Ruan, XZ
JF  - Gastroenterology Research and Practice
VL  - 2019
AV  - public
Y1  - 2019///
TI  - The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis
N1  - Copyright © 2019 Xiaoqian Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.http://creativecommons.org/licenses/by/4.0/
ER  -